Outlook Therapeutics, Inc. entered into a definitive securities purchase agreement for issuance pf common shares and accompanying warrants for gross proceeds of $65 million on January 23, 2024. The transaction included participation from new lead investor Great Point Partners, LLC, new investors Altium Capital Management LP, Caligan Partners, LP, Schonfeld Strategic Advisors LLC, Sphera Healthcare US Inc., Velan Capital Partners LP, Woodline Partners LP, returning investors Syntone Ventures LLC, Armistice Capital LLC, an undisclosed life science dedicated investor and another existing stockholder. The closing is conditioned upon stockholder approval of the transaction and certain other corporate actions, expected in the first quarter of 2024.